Novartis ends the VIBRANT-HD study and will not continue the program with Branaplam
Still the study brings us some very good news as the drug did reduce the levels of mutant (sick) huntingtin in the spinal fluid collected from the participants. This is groundbreaking achievement as the drug is administered orally (through the mouth). Nevertheless, reducing huntingtin in a safe way seems to be a challenging process. In August…
Read more